Immunological considerations for COVID-19 vaccine strategies

被引:0
|
作者
Mangalakumari Jeyanathan
Sam Afkhami
Fiona Smaill
Matthew S. Miller
Brian D. Lichty
Zhou Xing
机构
[1] McMaster University,McMaster Immunology Research Centre
[2] McMaster University,Department of Pathology and Molecular Medicine
[3] McMaster University,Michael G. DeGroote Institute for Infectious Disease Research
[4] McMaster University,Department of Biochemistry and Biomedical Sciences
来源
Nature Reviews Immunology | 2020年 / 20卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the most formidable challenge to humanity in a century. It is widely believed that prepandemic normalcy will never return until a safe and effective vaccine strategy becomes available and a global vaccination programme is implemented successfully. Here, we discuss the immunological principles that need to be taken into consideration in the development of COVID-19 vaccine strategies. On the basis of these principles, we examine the current COVID-19 vaccine candidates, their strengths and potential shortfalls, and make inferences about their chances of success. Finally, we discuss the scientific and practical challenges that will be faced in the process of developing a successful vaccine and the ways in which COVID-19 vaccine strategies may evolve over the next few years.
引用
收藏
页码:615 / 632
页数:17
相关论文
共 50 条
  • [21] COVID-19 vaccine results might inform malaria vaccine strategies
    Abeywickrema, Movin
    Goodman, Anna L.
    [J]. LANCET INFECTIOUS DISEASES, 2022, 22 (04): : 440 - 441
  • [22] Ethical Considerations of Offering Benefits to COVID-19 Vaccine Recipients
    Persad, Govind
    Emanuel, Ezekiel J.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 326 (03): : 221 - 222
  • [23] Ethical Considerations for COVID-19 Vaccine Trials in Correctional Facilities
    Wang, Emily A.
    Zenilman, Jonathan
    Brinkley-Rubinstein, Lauren
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 324 (11): : 1031 - 1032
  • [24] Correction to: Vaccine Considerations for Multiple Sclerosis in the COVID-19 Era
    Patricia K. Coyle
    Anne Gocke
    Megan Vignos
    Scott D. Newsome
    [J]. Advances in Therapy, 2022, 39 : 822 - 830
  • [25] COVID-19 Vaccine–Associated Myocarditis Considerations for Competitive Athletes
    Jason V. Tso
    Jonathan H. Kim
    [J]. Current Treatment Options in Cardiovascular Medicine, 2023, 25 : 573 - 585
  • [26] Psychological and Behavioral Predictors of Vaccine Efficacy: Considerations for COVID-19
    Madison, Annelise A.
    Shrout, M. Rosie
    Renna, Megan E.
    Kiecolt-Glaser, Janice K.
    [J]. PERSPECTIVES ON PSYCHOLOGICAL SCIENCE, 2021, 16 (02) : 191 - 203
  • [27] Vaccine and the Need To Be Heard: Considerations for COVID-19 Immunization in ESKD
    Srivatana, Vesh
    Wilkie, Caroline
    Perl, Jeffery
    Watnick, Suzanne
    [J]. KIDNEY360, 2021, 2 (06): : 1048 - 1050
  • [28] COVID-19 vaccine effectiveness and evolving variants: understanding the immunological footprint
    Zaeck, Luca M.
    GeurtsvanKessel, Corine H.
    de Vries, Rory D.
    [J]. LANCET RESPIRATORY MEDICINE, 2023, 11 (05): : 395 - 396
  • [29] An immunological autobiography: my year as a COVID-19 vaccine trial participant
    Kedl, Ross M.
    [J]. NPJ VACCINES, 2022, 7 (01)
  • [30] Equitable Vaccine Access in Light of COVID-19 Vaccine Procurement Strategies in Africa
    O'Hara, George L.
    Halabi, Sam
    Egbokhare, Olohikhuae
    [J]. COVID, 2024, 4 (02): : 276 - 288